Telotristat Ethyl

Phase 2

LEXICON PHARMACEUTICALS, INC. (LXRX)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Locally Advanced Unresectable Pancreatic Adenocarcinoma

View Full Landscape

Drug Information

Target Indication

Locally Advanced Unresectable Pancreatic Adenocarcinoma

Clinical Trial

NCT03910387

Last updated: 8/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/17/2017

Xermelo

Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

LXRX

LEXICON PHARMACEUTICALS, INC.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

SulfonylureaPhase 3

Type 2 Diabetes Mellitus

Telotristat etipratePhase 3

Carcinoid Syndrome

Sotagliflozin (SAR439954)Phase 3

Type 2 Diabetes Mellitus

SotagliflozinPhase 3

Type 2 Diabetes Mellitus

Insulin glargine (HOE901)Phase 3

Type 2 Diabetes Mellitus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts